CXCL8 and COVID-19: For example, the increased FES kinase in severe COVID‐19 can be addressed by repurposing Fostamatinib (a cancer drug) with the purpose of reducing organ damage via inhibition of TNF, IL‐8 and aggressive action of GM‐CSF.